Sign in
CompletedPhase 4

Glucocorticoids for Post-operative Patients With Acute Type A Aortic Dissection (The GLAD Trial)

Key facts

Who runs it
Shanghai Zhongshan Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
212 people enrolled
Started
7 Feb 2022
Ended
29 Nov 2023
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Methylprednisolone Injection
Record updated
26 December 2023

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Informed consent
  • Age above 18 years old (including 18 years old), regardless of gender
  • Confirmed type A aortic dissection with computer tomography and received surgical intervention
  • Life expectancy > 3 days after surgery

Who cannot take part

  • Glucocorticoid or any other anti-inflammatory drug usage in the past 14 days
  • Patients with pre-operative renal insufficiency (patients receiving renal replacement therapy before surgery)
  • History of cardiac surgery within the past 3 months or possible iatrogenic aortic dissection
  • Bacterial or fungal infection in the past 30 days
  • Allergic to glucocorticoid
  • Patients diagnosed with malignant tumor undergoing chemotherapy and immunotherapy
  • Pregnant
  • Implantation of ICD or permanent pacemaker
  • Patients with pre-operative severe liver dysfunction (CTP grade C)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is designed to evaluate the effects of glucocorticoid(GC) on improving post-operative organ dysfunction in patients with acute type A aortic dissection(aTAAD). Subjects with confirmed diagnosis of aTAAD undergoing surgical treatment will be enrolled and 1:1 randomly assigned to receive either glucocorticoids or normal treatment. All patients in the glucocorticoids group will be given methylprednisolone intravenously for 3 days after enrollment. The primary endpoint will be the amplitude of variation of Sequential Organ Failure Assessment score on post-operative day 4 compared to baseline.

The 2 groups in the trial

  • Glucocorticoid groupTreatment being tested

    Treatment: Methylprednisolone Injection

  • Control GroupNo study treatment, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessment of the Efficacy of Glucocorticoids in Improving Post-operative Organ Dysfunction in Patients With Acute Type A Aortic Dissection(GLAD): a Randomized Controlled Trial
Record updated
26 December 2023